JP2019535689A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535689A5
JP2019535689A5 JP2019522867A JP2019522867A JP2019535689A5 JP 2019535689 A5 JP2019535689 A5 JP 2019535689A5 JP 2019522867 A JP2019522867 A JP 2019522867A JP 2019522867 A JP2019522867 A JP 2019522867A JP 2019535689 A5 JP2019535689 A5 JP 2019535689A5
Authority
JP
Japan
Prior art keywords
fluoro
oxo
triazolo
benzamide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522867A
Other languages
English (en)
Japanese (ja)
Other versions
JP7680184B2 (ja
JP2019535689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/077301 external-priority patent/WO2018077944A2/en
Publication of JP2019535689A publication Critical patent/JP2019535689A/ja
Publication of JP2019535689A5 publication Critical patent/JP2019535689A5/ja
Priority to JP2022103480A priority Critical patent/JP2022130571A/ja
Priority to JP2024030029A priority patent/JP7747799B2/ja
Application granted granted Critical
Publication of JP7680184B2 publication Critical patent/JP7680184B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522867A 2016-10-27 2017-10-25 4,5-縮環1,2,4-トリアゾロン Active JP7680184B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022103480A JP2022130571A (ja) 2016-10-27 2022-06-28 4,5-縮環1,2,4-トリアゾロン
JP2024030029A JP7747799B2 (ja) 2016-10-27 2024-02-29 4,5-縮環1,2,4-トリアゾロン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/103642 2016-10-27
CNPCT/CN2016/103642 2016-10-27
PCT/EP2017/077301 WO2018077944A2 (en) 2016-10-27 2017-10-25 4,5-annulated 1,2,4-triazolones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022103480A Division JP2022130571A (ja) 2016-10-27 2022-06-28 4,5-縮環1,2,4-トリアゾロン

Publications (3)

Publication Number Publication Date
JP2019535689A JP2019535689A (ja) 2019-12-12
JP2019535689A5 true JP2019535689A5 (https=) 2020-12-03
JP7680184B2 JP7680184B2 (ja) 2025-05-20

Family

ID=60293935

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019522867A Active JP7680184B2 (ja) 2016-10-27 2017-10-25 4,5-縮環1,2,4-トリアゾロン
JP2022103480A Pending JP2022130571A (ja) 2016-10-27 2022-06-28 4,5-縮環1,2,4-トリアゾロン
JP2024030029A Active JP7747799B2 (ja) 2016-10-27 2024-02-29 4,5-縮環1,2,4-トリアゾロン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022103480A Pending JP2022130571A (ja) 2016-10-27 2022-06-28 4,5-縮環1,2,4-トリアゾロン
JP2024030029A Active JP7747799B2 (ja) 2016-10-27 2024-02-29 4,5-縮環1,2,4-トリアゾロン

Country Status (8)

Country Link
US (2) US10968216B2 (https=)
EP (1) EP3532474B1 (https=)
JP (3) JP7680184B2 (https=)
CN (2) CN114921391B (https=)
CA (1) CA3041650A1 (https=)
TW (1) TW201827430A (https=)
UY (1) UY37460A (https=)
WO (1) WO2018077944A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114921391B (zh) 2016-10-27 2024-01-02 拜耳股份有限公司 4,5-环状1,2,4-三唑酮
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
TW201945346A (zh) 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
TW202043208A (zh) * 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CA3152836A1 (en) * 2019-08-29 2021-03-04 Janssen Biotech, Inc. Substituted urea dihydroorotate dehydrogenase inhibitors
WO2021070132A1 (en) * 2019-10-10 2021-04-15 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
US12606540B2 (en) 2020-05-29 2026-04-21 Medshine Discovery Inc. Triazolone compound
EP4185577A4 (en) * 2020-07-14 2024-08-07 Nanjing Zenshine Pharmaceuticals Co., Ltd. Compounds as dhodh inhibitors
CN111773214B (zh) * 2020-07-17 2021-04-20 中国人民解放军军事科学院军事医学研究院 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途
WO2022070069A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
BR112023021068A2 (pt) * 2021-04-16 2024-01-23 Hotspot Therapeutics Inc Compostos, composições e métodos para tratar câncer
WO2023280181A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途
CN118284603A (zh) * 2021-11-26 2024-07-02 南京明德新药研发有限公司 三氮唑酮类化合物的晶型及其应用
JP2025523057A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド がん処置における使用のためのcbl-b阻害剤及び抗pd1/抗pd-l1
EP4554582A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627901A1 (de) 1996-07-11 1998-01-15 Bayer Ag Substituierte aromatische Carbonylverbindungen und ihre Derivate
DE19901846A1 (de) 1999-01-19 2000-07-20 Bayer Ag Substituierte Arylheterocyclen
US6444613B1 (en) 1999-03-12 2002-09-03 Hoechst Schering Agrevo Gmbh Defoliant
JP2005512502A (ja) * 2000-10-30 2005-05-12 ファルマシア・コーポレーション アスペルギルス・オクラセウス(Aspergillusochraceus)11アルファ水酸化酵素および酸化還元酵素
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
EP2373645A4 (en) 2008-12-08 2012-05-02 Sirtris Pharmaceuticals Inc ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS
WO2010115736A2 (en) 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
AU2011343222B2 (en) * 2010-12-16 2016-09-29 Pharmazell Gmbh Novel 7B-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
ES2911701T3 (es) * 2012-11-01 2022-05-20 Univ British Columbia Polipéptidos de citocromo P450 y citocromo P450 reductasa, moléculas de ácido nucleico codificantes y usos de los mismos
HRP20181908T1 (hr) 2013-02-25 2019-01-11 Aurigene Discovery Technologies Limited Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze
CN104561093A (zh) * 2014-12-25 2015-04-29 华东师范大学 一种重组人源CYP3A4/CPR/cyt b5蛋白共转染共表达的方法
US20160251341A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted triazole compounds as serine protease inhibitors
CN106543139B (zh) 2015-09-17 2020-03-17 沈阳中化农药化工研发有限公司 一种三唑酮类化合物及其用途
JOP20190094A1 (ar) * 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
CN114921391B (zh) 2016-10-27 2024-01-02 拜耳股份有限公司 4,5-环状1,2,4-三唑酮
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
TW201945346A (zh) * 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
US20190307728A1 (en) * 2018-04-10 2019-10-10 Bayer Pharma Aktiengesellschaft Methods of treatment with a 2,4,5-trisubstituted 1,2,4-triazolone
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2019535689A5 (https=)
JP7001682B2 (ja) 置換1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン及びGLUN2B受容体調節因子としてのそれらの使用
RU2717238C2 (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
US9216999B2 (en) Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors
KR102650565B1 (ko) Pde9 억제제 및 이의 용도
JP4814783B2 (ja) ピラゾロピリジン誘導体
TWI850648B (zh) 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
RU2689777C1 (ru) Конденсированные трициклические производные бензимидазолов в качестве модуляторов активности tnf
KR102319857B1 (ko) P2x7 조절제
AU2020348675B2 (en) Azole-fused pyridazin-3(2H)-one derivatives
CA3198809A1 (en) Heterocyclic spiro compounds and methods of use
AU2019280356A1 (en) ERK inhibitor and use thereof
WO2013088257A1 (en) Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
EA025520B1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TW202115075A (zh) 咪唑并[1,2-a]吡啶基衍生物及其在疾病治療中之用途
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
CN116262739A (zh) 含氮芳基衍生物调节剂、其制备方法和应用
US20240383875A1 (en) Benzimidazole Pyridine Derivatives
CN120418238A (zh) 新颖苯并咪唑衍生物
WO2025017078A1 (en) New pyrazolopyridine derivatives
JP2025523848A (ja) チロシンキナーゼ2阻害剤及びその使用
JP2025523507A (ja) チロシンキナーゼ2阻害剤及びその使用
JP2024504788A (ja) ピラゾールアミド誘導体
HK40008526B (zh) P2x7调节剂
OA18225A (en) Aminopyrimidinyl compounds as Jak inhibitors.